Core Viewpoint - Chengdu enterprises are actively engaging in the capital market, with several companies from the semiconductor and biopharmaceutical sectors initiating IPO processes, indicating the city's growth vitality and potential in these industries [1][2]. Semiconductor Sector - The semiconductor industry in Chengdu is experiencing significant growth, with companies like Chengdu Super Pure Materials Co., Ltd. and Chengdu Starway Microelectronics Co., Ltd. leading the charge in IPO applications [3][4]. - Chengdu Super Pure Materials aims to raise 1.12468 billion yuan through its IPO, focusing on precision components for semiconductor manufacturing and optical fields, holding a 5.7% market share in mainland China [4][6]. - Chengdu Starway Microelectronics, founded in 2019, has initiated its A-share IPO process and has secured over 230 invention patents, emphasizing its strong R&D capabilities [6][8]. Biopharmaceutical Sector - Chengdu has a well-established biopharmaceutical industry, transitioning from generic drugs to innovative drug development, with companies like Zeling Biopharmaceutical Technology Co., Ltd. and Olin Bio leading recent IPO efforts [9][10]. - Zeling Biopharmaceutical completed a 600 million yuan Series C financing round and has submitted its IPO application to the Hong Kong Stock Exchange shortly after [10][13]. - Olin Bio, a veteran in the vaccine sector, has also applied for an H-share listing on the Hong Kong Stock Exchange, highlighting the ongoing growth in Chengdu's biopharmaceutical landscape [13]. Diverse Industry Growth - Chengdu is witnessing a surge in various sectors, with many companies characterized as "specialized, refined, and innovative" preparing for IPOs [14][18]. - Companies like Sentai Precision Tools Co., Ltd. and Hongming Electronics Co., Ltd. are making strides in their respective fields, with Sentai completing IPO counseling for the Beijing Stock Exchange and Hongming successfully passing the IPO review for the Shenzhen Stock Exchange [15][17]. - The "Rongyi Shang" system in Chengdu is facilitating a supportive environment for IPOs, with over 700 potential listing companies and 2,900 high-growth enterprises being nurtured [18].

招股书显示，超纯股份是一家专注于特殊涂层工艺及其关联技术和材料的国家级专精特新重点"小巨人"企 业，主要面向芯片制造、精密光学等领域，提供经材料改性、精密表面加工、精密清洗和特殊涂层工艺后 的精密零部件产品及服务。 全球市场长期由欧美日企业主导，KoMiCo、TOTO、TOCALO 等跨国企业凭借先发技术优势和全球化布 局，在先进制程领域占据绝对主导地位。 智通财经APP获悉，1月15日，成都超纯应用材料股份有限公司(简称：超纯股份)申请深交所创业板上市审 核状态变更为"已问询"，华泰联合证券为其保荐机构，拟募资11.2468亿元。 超纯股份主营产品覆盖了晶圆制造、封装以及硅片制造领域设备核心零部件，在刻蚀、光刻、量检测、退 火和薄膜沉积设备领域取得较为突出的技术优势，并且在键合、离子注入、扩散等设备领域小批量量产或 正在进行客户端验证，并为硅外延片制造设备提供关键零部件产品。公司系国内极少数 5nm 及以下制程 半导体刻蚀设备核心零部件的供应商。 实际募集资金扣除发行等费用后，拟按照轻重缓急投资以下项目： 财务方面，于2022年度、2023年度、2024年度以及2025年1-6月，超纯股份营业收入分别约为1 ...

北京商报讯（记者 王蔓蕾）1月15日晚间，深交所官网显示，成都超纯应用材料股份有限公司（以下简 称"超纯股份"）创业板IPO进入问询阶段。 本次冲击上市，超纯股份拟募集资金约11.25亿元。 据了解，超纯股份是一家专注于特殊涂层工艺及其关联技术和材料的国家级专精特新重点"小巨人"企 业，主要面向芯片制造、精密光学等领域，提供经材料改性、精密表面加工、精密清洗和特殊涂层工艺 后的精密零部件产品及服务。公司IPO于2025年12月30日获得受理。 ...